Inflammatory Skin Disease

Calcipotriol/betamethasone dipropionate, or CAL/BDP, combination cream vs. foam had higher satisfaction ratings among patients with psoriasis, suggesting the cream formulation may increase adherence, according to a study.

“It’s a very exciting time in inflammatory skin diseases,” Emma Guttman-Yassky, MD, PhD, told Healio.

While FDA- and EU-approved JAK inhibitors have shown comparable efficacy and safety across a spectrum of immune-mediated diseases, more study is required to fully parse the mechanism of action, according to a presenter at the 2020 Interdisciplinary Autoimmune Summit.

Kubota Vision and Leo Pharma have entered into an open innovation agreement to screen novel vascular adhesion protein-1 inhibitor compounds, according to a press release.

Upadacitinib reduced all clinical disease measures including itch-related outcomes at 16 weeks in patients with moderate to severe atopic dermatitis, according to phase 2b study results published in Journal of Allergy and Clinical Immunology.

LEO Pharma announced that tralokinumab met all primary and secondary endpoints in ECZTRA 1-3, its three pivotal phase 3 studies for moderate to severe atopic dermatitis in adults.

In a top Healio Dermatology story, preliminary findings from Emma Guttman-Yassky, MD, PhD, demonstrate a novel use of dupilumab for managing chronic keloids with reductions in skin fibrosis and keloidal scarring, which may suggest a potential underlying Th2 pathogenesis in keloid formation.

Patients hospitalized for dermatologic issues with concomitant micronutrient deficiencies had a significantly increased length of stay and higher 30-day mortality rates, according to a study.

Preliminary findings from Emma Guttman-Yassky, MD, PhD, and colleagues demonstrate a novel use of dupilumab for managing chronic keloids with reductions in skin fibrosis and keloidal scarring, which may suggest a potential underlying Th2 pathogenesis in keloid formation.